Prostate cancer is the most common cancer among men in the U.S. and the second leading cause of cancer death. Yet, the traditional testing method, monitoring PSA, is just one piece in a complicated puzzle.
Knowing why a PSA is elevated, what the individual’s level of risk is, and if further testing is required create an important, full picture for predictive decision making.
MPS2 is a non-invasive urine test, offering a new level of simple, actionable, and data-driven decision making for both providers and patients.
You deserve the next generation in prostate cancer risk prediction for men’s health.